Development of Fluoroquinolone Resistance through Antibiotic Tolerance in Campylobacter jejuni. 2022

Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
Division of Environmental Health Sciences, School of Public Health, University of Minnesotagrid.17635.36, Saint Paul, Minnesota, USA.

Antibiotic tolerance not only enables bacteria to survive acute antibiotic exposures but also provides bacteria with a window of time in which to develop antibiotic resistance. The increasing prevalence of Campylobacter jejuni isolates resistant to clinically important antibiotics, particularly fluoroquinolones (FQs), is a global public health concern. Currently, little is known about antibiotic tolerance and its effects on resistance development in C. jejuni. Here, we show that exposure to ciprofloxacin or tetracycline at concentrations 10 and 100 times higher than the MIC induces antibiotic tolerance in C. jejuni, whereas gentamicin or erythromycin treatment causes cell death. Interestingly, FQ resistance rapidly develops in C. jejuni after tolerance induction by ciprofloxacin and tetracycline. Furthermore, after tolerance is induced, alkyl hydroperoxide reductase (AhpC) plays a critical role in reducing FQ resistance development by alleviating oxidative stress. Together, these results demonstrate that exposure of C. jejuni to antibiotics can induce antibiotic tolerance and that FQ-resistant (FQR) C. jejuni clones rapidly emerge after tolerance induction. This study elucidates the mechanisms underlying the high prevalence of FQR C. jejuni and provides insights into the effects of antibiotic tolerance on resistance development. IMPORTANCE Antibiotic tolerance compromises the efficacy of antibiotic treatment by extending bacterial survival and facilitating the development of mutations associated with antibiotic resistance. Despite growing public health concerns about antibiotic resistance in C. jejuni, antibiotic tolerance has not yet been investigated in this important zoonotic pathogen. Here, our results show that exposure of C. jejuni to ciprofloxacin or tetracycline leads to antibiotic tolerance development, which subsequently facilitates the emergence of FQR C. jejuni. Importantly, these antibiotics are commonly used in animal agriculture. Moreover, our study suggests that the use of non-FQ drugs in animal agriculture promotes FQ resistance development, which is crucial because antibiotic-resistant C. jejuni is primarily transmitted from animals to humans. Overall, these findings increase our understanding of the mechanisms of resistance development through the induction of antibiotic tolerance.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D013752 Tetracycline A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis. 4-Epitetracycline,Achromycin,Achromycin V,Hostacyclin,Sustamycin,Tetrabid,Tetracycline Hydrochloride,Tetracycline Monohydrochloride,Topicycline,4 Epitetracycline
D016123 Campylobacter jejuni A species of bacteria that resemble small tightly coiled spirals. Its organisms are known to cause abortion in sheep and fever and enteritis in man and may be associated with enteric diseases of calves, lambs, and other animals. Campylobacter fetus subsp. jejuni,Vibrio hepaticus,Vibrio jejuni
D054464 Peroxiredoxins A family of ubiquitously-expressed peroxidases that play a role in the reduction of a broad spectrum of PEROXIDES like HYDROGEN PEROXIDE; LIPID PEROXIDES and peroxinitrite. They are found in a wide range of organisms, such as BACTERIA; PLANTS; and MAMMALS. The enzyme requires the presence of a thiol-containing intermediate such as THIOREDOXIN as a reducing cofactor. Peroxiredoxin,Alkyl Hydroperoxide Reductase,Alkyl Hydroperoxide Reductase C,Alkyl Hydroperoxide Reductase D,Alkylhydroperoxide Reductase,Peroxidoxin,Peroxiredoxin 1,Peroxiredoxin 2,Peroxiredoxin 4,Peroxiredoxin 5,Peroxiredoxin I,Peroxiredoxin II,Peroxiredoxin IV,Peroxiredoxin V,Peroxiredoxin-4,Protector Protein (Mixed-Function Oxidase Systems),Thiol-Specific Antioxidant Protein,Thioredoxin Peroxidase,Thioredoxin Peroxidase 1,Thioredoxin Peroxidase 2,Thioredoxin Peroxidase PMP20,Thioredoxin-Dependent Peroxide Reductase 1,Thioredoxin-Dependent Peroxide Reductase 2,Hydroperoxide Reductase, Alkyl,Thiol Specific Antioxidant Protein,Thioredoxin Dependent Peroxide Reductase 1,Thioredoxin Dependent Peroxide Reductase 2
D024841 Fluoroquinolones A group of QUINOLONES with at least one fluorine atom and a piperazinyl group. Fluoroquinolone

Related Publications

Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
June 2011, Microbial drug resistance (Larchmont, N.Y.),
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
June 2008, PLoS pathogens,
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
December 2007, FEMS microbiology letters,
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
December 2002, Emerging infectious diseases,
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
May 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
April 2022, Antibiotics (Basel, Switzerland),
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
September 2010, Foodborne pathogens and disease,
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
October 1991, Antimicrobial agents and chemotherapy,
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
November 1991, The Journal of infection,
Myungseo Park, and Jinshil Kim, and Jill Feinstein, and Kevin S Lang, and Sangryeol Ryu, and Byeonghwa Jeon
October 2022, Antibiotics (Basel, Switzerland),
Copied contents to your clipboard!